# Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II

> **NCT00796653** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 937 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Olodaterol (BI 1744)
- **DRUG:** Olodaterol (BI 1744)
- **DRUG:** Formoterol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00796653
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-12
- **Final completion:** —
- **Target enrollment:** 937 (ACTUAL)
- **Last updated:** 2014-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00796653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00796653, "Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00796653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*